NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy

Inclusion Criteria

• •Age between 18 and 70 years old
• •Patients with histologically confirmed unilateral invasive ductal
• •carcinoma(according to WHO histologically type)
• •Tumor clinical staged as IIB-IIIB before neoadjuvant chemotherapy (according to the 7th AJCC edition).
• •After standard treatment (6-8 cycles) of neoadjuvant chemotherapy (plan formulated by the attending doctor, including anthracycline and paclitaxel drugs, must not contain platinum), assessed by the surgery, the original site for non - pCR (MP class 1-4) or lymph nodes are still positive for patients.
• •Luminal B breast cancer defined as positive oestrogen and/or progesterone receptors, a negative HER2 defined as negative ISH test or an IHC status of 0 or 1+ as per local laboratory testing and a Ki67 \> 14%.
• •No evidence of distant metastasis in the clinical or radiological aspects of preoperative. examination,that is M0.
• •Patients without peripheral neuropathy or I peripheral neurotoxicity.
• •Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1.
• •Patients recovered well after surgery, at least 1 weeks after the operation.
• •Adequate marrow: White blood cells count≥3000/μL,neutrophil count ≥1500/μL, hemoglobin ≥9g/dL and platelet count ≥75000/μL.
• •Normal liver function test: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) ≤ 1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤ 2.5×ULN, and bilirubin ≤ 1.5ULN.
• •Adequate renal function: Serum creatinine ≤ 1.5ULN.
• •Contraception during the treatment of child-bearing women.
• •Adequate cardiac function :Left ventricular ejection fraction (LVEF) \> 50%.
• •Patients must be informed of the investigational nature of this study and give written informed consent.
• •Patients without serious heart, lung, liver, kidney and other important organs disease history.
• •Patients have good compliance.